Centrally administered adrenomedullin 2 activates hypothalamic oxytocin-secreting neurons, causing elevated plasma oxytocin level in rats

Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E753-61. doi: 10.1152/ajpendo.00042.2005. Epub 2005 Jun 14.

Abstract

We examined the effects of intracerebroventricular (i.c.v.) administration of adrenomedullin 2 (AM2) on plasma oxytocin (OXT) and arginine vasopressin (AVP) levels in conscious rats. Plasma OXT levels were markedly increased 5 min after i.c.v. administration of AM2 (1 nmol/rat) compared with vehicle and remained elevated in samples taken at 10, 15, 30, and 60 min. By contrast, plasma AVP levels were not significantly elevated in samples taken between 5 and 180 min after i.c.v. administration of AM2 except at the 30-min time point. Fos-like immunoreactivity (Fos-LI) was observed in various brain areas, including the paraventricular (PVN) and the supraoptic nuclei (SON) after i.c.v. administration of AM2 (2 nmol/rat) in conscious rats (measured at 90 min post-AM2 infusion). Dual immunostaining for OXT/Fos and AVP/Fos showed that OXT-LI neurons predominantly exhibited nuclear Fos-LI compared with AVP-LI neurons in the PVN and the SON. In situ hybridization histochemistry showed that i.c.v. administration of AM2 (0.2, 1, and 2 nmol/rat) caused marked induction of the expression of the c-fos gene in the PVN and the SON. This induction was significantly reduced by pretreatment with both the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) (3 nmol/rat) and the AM receptor antagonist AM-(22-52) (27 nmol/rat). These results suggest that centrally administered AM2 mainly activates OXT-secreting neurons in the PVN and the SON, at least in part through the CGRP and/or AM receptors with marked elevation of plasma OXT levels in conscious rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenomedullin
  • Animals
  • Arginine Vasopressin / antagonists & inhibitors
  • Arginine Vasopressin / blood
  • Arginine Vasopressin / metabolism
  • Calcitonin Gene-Related Peptide / pharmacology
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Immunohistochemistry
  • In Situ Hybridization
  • Injections, Intraventricular
  • Male
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neuropeptides / pharmacology*
  • Oxytocin / antagonists & inhibitors
  • Oxytocin / blood*
  • Oxytocin / metabolism
  • Paraventricular Hypothalamic Nucleus / cytology
  • Paraventricular Hypothalamic Nucleus / drug effects*
  • Paraventricular Hypothalamic Nucleus / metabolism
  • Peptide Fragments / pharmacology
  • Proto-Oncogene Proteins c-fos / biosynthesis
  • Proto-Oncogene Proteins c-fos / genetics
  • Rats
  • Rats, Wistar
  • Supraoptic Nucleus / cytology
  • Supraoptic Nucleus / drug effects*
  • Supraoptic Nucleus / metabolism

Substances

  • Adm2 protein, rat
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • Neuropeptides
  • Peptide Fragments
  • Proto-Oncogene Proteins c-fos
  • adrenomedullin (22-52)
  • Arginine Vasopressin
  • calcitonin gene-related peptide (8-37)
  • Adrenomedullin
  • Oxytocin
  • Calcitonin Gene-Related Peptide